Chronic kidney disease
From damage-oriented to function-oriented diagnostics
Current biomarkers available for the detection of an impaired kidney function, such as serum creatinine or urinary albumin, lack the sensitivity for early-enough detection. For example, creatinine stays within the reference range until a third or even half of the kidneys' function has been lost.
Metabolomic biomarkers will allow kidney disease to be detected at an early stage and functional recovery after kidney transplantation to be monitored. In addition, metabolomic biomarkers are expected to have great prognostic potential. Currently, it is impossible to predict the individual progression rate from moderate to end-stage renal disease requiring hemodialysis and kidney transplantation. The Biocrates biomarker candidates have the potential for highly accurate staging and monitoring, enabling optimized disease management, e.g., in terms of hyperglycemia, hyperlipidemia, and hypertension, which clinical experts believe will prolong the individual time to hemodialysis by up to 10 years.
